An Open-label Pilot Study of Transdermal Selegiline for Depression in Parkinson's Disease Patients

Authors

A. Ray
Marty L. Eng, Cedarville UniversityFollow
K. E. Lyons
R. Pahwa

Document Type

Conference Presentation

Event Date

4-2008

Conference/Event

12th International Congress of Parkinson's Disease and Movement Disorders

Location

Chicago, IL

Abstract

Depression is one of the most common non-motor symptoms of PD with reported prevalence rates from 40 to 80%. Transdermal selegiline was recently approved for the treatment of depression. There have been no reports of transdermal selegiline for depression in PD patients; however, other forms of selegiline have been shown to be effective treatments for controlling PD symptoms. The goal of this study was to determine if transdermal selegiline can reduce depression without worsening and potentially improving the symptoms of PD.

Keywords

Parkinson's Disease, depression

Comments

This poster session is item number 931.

Recommended Citation

Ray, A.; Eng, Marty L.; Lyons, K. E.; and Pahwa, R., "An Open-label Pilot Study of Transdermal Selegiline for Depression in Parkinson's Disease Patients" (2008). Pharmacy Practice Faculty Presentations. 270.
https://digitalcommons.cedarville.edu/pharmacy_practice_presentations/270